Broadly Neutralizing Antibodies for HIV-1 Prevention

被引:43
|
作者
Walsh, Stephen R. [1 ]
Seaman, Michael S. [2 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA
来源
FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷
关键词
HIV-1; antibody; neutralizing; Fc effector function; clinical trial; HUMAN MONOCLONAL-ANTIBODIES; POTENT NEUTRALIZATION; ANTI-HIV-1; ANTIBODIES; PASSIVE IMMUNOTHERAPY; IMPROVES PROTECTION; GLYCAN RECOGNITION; EFFECTOR FUNCTIONS; FC-RECEPTOR; THERAPY; BREADTH;
D O I
10.3389/fimmu.2021.712122
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Given the absence of an effective vaccine for protection against HIV-1 infection, passive immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block acquisition of HIV-1 are being rigorously pursued in the clinical setting. bnAbs have demonstrated robust protection in preclinical animal models, and several leading bnAb candidates have shown favorable safety and pharmacokinetic profiles when tested individually or in combinations in early phase human clinical trials. Furthermore, passive administration of bnAbs in HIV-1 infected individuals has resulted in prolonged suppression of viral rebound following interruption of combination antiretroviral therapy, and robust antiviral activity when administered to viremic individuals. Recent results from the first efficacy trials testing repeated intravenous administrations of the anti-CD4 binding site bnAb VRC01 have demonstrated positive proof of concept that bnAb passive immunization can confer protection against HIV-1 infection in humans, but have also highlighted the considerable barriers that remain for such strategies to effectively contribute to control of the epidemic. In this review, we discuss the current status of clinical studies evaluating bnAbs for HIV-1 prevention, highlight lessons learned from the recent Antibody Mediated Prevention (AMP) efficacy trials, and provide an overview of strategies being employed to improve the breadth, potency, and durability of antiviral protection.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Broadly neutralizing antibodies for HIV-1 prevention and therapy
    Julg, Boris
    Barouch, Dan
    [J]. SEMINARS IN IMMUNOLOGY, 2021, 51
  • [2] Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
    Stephenson, Kathryn E.
    Wagh, Kshitij
    Korber, Bette
    Barouch, Dan H.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 38, 2020, 38 : 673 - 703
  • [3] Use of broadly neutralizing antibodies for HIV-1 prevention
    Pegu, Amarendra
    Hessell, Ann J.
    Mascola, John R.
    Haigwood, Nancy L.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 275 (01) : 296 - 312
  • [4] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Cohen, Yehuda Z.
    Caskey, Marina
    [J]. CURRENT OPINION IN HIV AND AIDS, 2018, 13 (04) : 366 - 373
  • [5] Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection
    Awan, Seemal F.
    Happe, Myra
    Hofstetter, Amelia R.
    Gama, Lucio
    [J]. CURRENT OPINION IN HIV AND AIDS, 2022, 17 (04) : 247 - 257
  • [6] FOCUS ON RESEARCH Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy
    Caskey, Marina
    Klein, Florian
    Nussenzweig, Michel C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2019 - 2021
  • [7] The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
    Thavarajah, Jannifer Jasmin
    Honge, Bo Langhoff
    Wejse, Christian Morberg
    [J]. VIRUSES-BASEL, 2024, 16 (06):
  • [8] Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention
    Becerra, Juan C.
    Hitchcock, Lauren
    Vu, Khoa
    Gach, Johannes S.
    [J]. MICROBIAL CELL, 2024, 11 (01):
  • [9] Broadly neutralizing antibodies to prevent HIV-1
    Cohen, Myron S.
    Corey, Lawrence
    [J]. SCIENCE, 2017, 358 (6359) : 46 - 47
  • [10] Coevolution of HIV-1 and broadly neutralizing antibodies
    Doria-Rose, Nicole A.
    Landais, Elise
    [J]. CURRENT OPINION IN HIV AND AIDS, 2019, 14 (04) : 286 - 293